Elon’s New Device is About to Shock the World

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

Click here to see the details because there’s a lot of money at stake.

John F. Hamilton net worth and biography

John Hamilton Biography and Net Worth

Director of Aridis Pharmaceuticals

Previously, he served as a director and audit chair of three companies: Vermillion, Inc. from 2008 to 2013; Anesiva, Inc. in 2009; and Encompass Funds from 2012 to 2015. From 1997 until his retirement in 2007, Mr. Hamilton served as Vice President and Chief Financial Officer of Depomed, Inc., a specialty pharmaceutical company. Mr. Hamilton began his career in international banking with The Philadelphia National Bank and Crocker National Bank and went on to hold senior financial positions at several biopharmaceutical companies, including Glyko, Inc., which is now BioMarin Pharmaceuticals, and Chiron Corporation (acquired by Novartis). He sits on the regional Board of Directors of the Association of Bioscience Financial Officers. Mr. Hamilton received his M.B.A. from the University of Chicago and B.A. from the University of Pennsylvania.

How do I contact John F. Hamilton?: The corporate mailing address for Mr. Hamilton and other Aridis Pharmaceuticals executives is 5941 Optical Ct, San Jose CA, 95138. Aridis Pharmaceuticals can also be reached via phone at (408) 385-1742 and via email at [email protected]. Learn More on John F. Hamilton's contact information.
Has John F. Hamilton been buying or selling shares of Aridis Pharmaceuticals?: John F. Hamilton has not been actively trading shares of Aridis Pharmaceuticals in the last ninety days. Most recently, on Tuesday, July 27th, John F. Hamilton bought 2,000 shares of Aridis Pharmaceuticals stock. The stock was acquired at an average cost of $4.87 per share, with a total value of $9,740.00. Following the completion of the transaction, the director now directly owns 702,132 shares of the company's stock, valued at $3,419,382.84. Learn More on John F. Hamilton's trading history.
Who are Aridis Pharmaceuticals' active insiders?: Aridis Pharmaceuticals' insider roster includes John Hamilton (Director), and Vu Truong (CEO). Learn More on Aridis Pharmaceuticals' active insiders.

John F. Hamilton Insider Trading History at Aridis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/27/2021	Buy	2,000	$4.87	$9,740.00	702,132

John F. Hamilton Buying and Selling Activity at Aridis Pharmaceuticals

Aridis Pharmaceuticals Company Overview

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Today's Range

Now: $0.06

$0.06

50 Day Range

MA: $0.07

$0.06

$0.08

2 Week Range

Now: $0.06

$0.05

$0.54

Volume

28,923 shs

Average Volume

80,441 shs

Market Capitalization

$2.95 million

P/E Ratio

N/A

Dividend Yield